Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome

Rada V. Moerman; Suzanne Arends; Petra M. Meiners; Arjan Vissink; Frederik K. L. Spijkervet; Frans G. M. Kroese; Elisabeth Brouwer; Hendrika Bootsma

doi:10.3899/jrheum.160459

Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome

Rada V. Moerman, Suzanne Arends, Petra M. Meiners, Arjan Vissink, Frederik K. L. Spijkervet, Frans G. M. Kroese, Elisabeth Brouwer, Hendrika Bootsma^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjoren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjoren syndrome (pSS).

Methods. Patients with pSS treated with RTX (n = 18) or ABA ( n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C- reactive protein (CRP) level >= 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.

Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.

Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.

Original language	English
Pages (from-to)	292-296
Number of pages	5
Journal	The Journal of Rheumatology
Volume	44
Issue number	3
DOIs	https://doi.org/10.3899/jrheum.160459
Publication status	Published - Mar-2017

Keywords

PRIMARY SJÖGREN SYNDROME
ARTICULAR INVOLVEMENT
28-JOINT DISEASE ACTIVITY SCORE
ESSDAI ARTICULAR DOMAIN
BIOLOGICALS

Access to Document

10.3899/jrheum.160459

Handle.net

Persistent link

Embargoed Document

Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome
Final publisher's version, 282 KB

Cite this

@article{802b0fb91a8747529965d5daee3e388a,

title = "Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome",

abstract = "Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjoren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjoren syndrome (pSS).Methods. Patients with pSS treated with RTX (n = 18) or ABA ( n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C- reactive protein (CRP) level >= 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.",

keywords = "PRIMARY SJ{\"O}GREN SYNDROME, ARTICULAR INVOLVEMENT, 28-JOINT DISEASE ACTIVITY SCORE, ESSDAI ARTICULAR DOMAIN, BIOLOGICALS",

author = "Moerman, {Rada V.} and Suzanne Arends and Meiners, {Petra M.} and Arjan Vissink and Spijkervet, {Frederik K. L.} and Kroese, {Frans G. M.} and Elisabeth Brouwer and Hendrika Bootsma",

year = "2017",

month = mar,

doi = "10.3899/jrheum.160459",

language = "English",

volume = "44",

pages = "292--296",

journal = "The Journal of Rheumatology",

issn = "0315-162X",

publisher = "J RHEUMATOL PUBL CO",

number = "3",

}

TY - JOUR

T1 - Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome

AU - Moerman, Rada V.

AU - Arends, Suzanne

AU - Meiners, Petra M.

AU - Vissink, Arjan

AU - Spijkervet, Frederik K. L.

AU - Kroese, Frans G. M.

AU - Brouwer, Elisabeth

AU - Bootsma, Hendrika

PY - 2017/3

Y1 - 2017/3

N2 - Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjoren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjoren syndrome (pSS).Methods. Patients with pSS treated with RTX (n = 18) or ABA ( n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C- reactive protein (CRP) level >= 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.

AB - Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjoren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjoren syndrome (pSS).Methods. Patients with pSS treated with RTX (n = 18) or ABA ( n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C- reactive protein (CRP) level >= 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.

KW - PRIMARY SJÖGREN SYNDROME

KW - ARTICULAR INVOLVEMENT

KW - 28-JOINT DISEASE ACTIVITY SCORE

KW - ESSDAI ARTICULAR DOMAIN

KW - BIOLOGICALS

U2 - 10.3899/jrheum.160459

DO - 10.3899/jrheum.160459

M3 - Article

C2 - 28089983

SN - 0315-162X

VL - 44

SP - 292

EP - 296

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

IS - 3

ER -

Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this